A modified device for subretinal injection

Retina ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Tingkun Shi ◽  
Haixia Xie ◽  
Haoyu Chen
Keyword(s):  
Subretinal Injection

scholarly journals Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration

2014 ◽  
Vol 35 (1) ◽  
pp. 169-176 ◽  
Author(s):  
CHAOQI LIU ◽  
LINING CAO ◽  
SHUAI YANG ◽  
LINXINYU XU ◽  
PEI LIU ◽  
...  
Keyword(s):  
Retinal Degeneration ◽  
Amyloid Β ◽  
Cell Senescence ◽  
Amyloid Β Peptide ◽  
Subretinal Injection

scholarly journals Retinal cell type expression specificity of HIV-1-derived gene transfer vectors upon subretinal injection in the adult rat: influence of pseudotyping and promoter

2005 ◽  
Vol 7 (10) ◽  
pp. 1367-1374 ◽  
Author(s):  
Alexis-Pierre Bemelmans ◽  
Sébastien Bonnel ◽  
Leïla Houhou ◽  
Noëlle Dufour ◽  
Emeline Nandrot ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Retinal Cell ◽  
Cell Type ◽  
Adult Rat ◽  
Transfer Vectors ◽  
Hiv 1 ◽  
Subretinal Injection

Accidental Subretinal Injection of Triamcinolone Acetonide

1998 ◽  
Vol 29 (11) ◽  
pp. 935-938
Author(s):  
Mehdi Modarres ◽  
Mohammad M Parvaresh ◽  
Gholam A Peyman
Keyword(s):  
Triamcinolone Acetonide ◽  
Subretinal Injection

Optimized Subretinal Injection Technique for Gene Therapy Approaches

2019 ◽  
pp. 405-412 ◽  
Author(s):  
Regine Mühlfriedel ◽  
Stylianos Michalakis ◽  
Marina Garcia Garrido ◽  
Vithiyanjali Sothilingam ◽  
Christian Schön ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Injection Technique ◽  
Subretinal Injection

Challenges in non-viral ocular gene transfer

2007 ◽  
Vol 35 (1) ◽  
pp. 47-49 ◽  
Author(s):  
L. Peeters ◽  
N.N. Sanders ◽  
J. Demeester ◽  
S.C. De Smedt
Keyword(s):  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Viral Gene ◽  
Target Tissue ◽  
Long Distance ◽  
Promising Alternative ◽  
Gene Complexes ◽  
Poly Ethylene ◽  
Review Reports ◽  
Subretinal Injection

Nowadays, there is no effective treatment for many retinal disorders. Knowledge of the genetic basis of many severe ocular diseases may allow for alternative treatments by gene therapy. Non-viral gene complexes, such as lipo- and poly-plexes, can be delivered to the posterior segment, most often the target tissue, by intravitreal or subretinal injection. Since subretinal injections are very invasive, intravitreal injection is a promising alternative route to deliver gene complexes into the eye. However, the drawback of this technique is the relative long distance the complexes have to travel through the vitreous gel before they reach the retina. This mini-review reports on how non-viral gene complexes behave in vitreous. It especially focuses on how the coating of lipoplexes with poly(ethylene glycol) influences their behaviour in vitreous and the transfection of retinal pigment epithelium.

scholarly journals Surgical treatment of «dry» forms of central chorioretinal dystrophy with the use of platelet-rich blood autoplasma

2017 ◽  
Vol 98 (3) ◽  
pp. 390-393
Author(s):  
D G Arsjutov
Keyword(s):  
Surgical Treatment ◽  
Pigment Epithelium ◽  
Vitreoretinal Surgery ◽  
Internal Limiting Membrane ◽  
Hyaline Membrane ◽  
The Impact ◽  
Observation Period ◽  
Subretinal Injection ◽  
Sodium Solution

Aim. To study the impact of platelet-rich blood autoplasma on the capability of the retinal regeneration in nonexudative forms of central chorioretinal dystrophy with the use of microinvasive vitreoretinal surgery. Methods. Surgical treatment was performed on 14 patients with central chorioretinal dystrophy aged 29 to 87 years. The surgery technique consisted of 3-port 25+, 27 Ga vitrectomy with posterior hyaline membrane and internal limiting membrane peel with subsequent central retinal exfoliation with 38 Ga cannula and balanced sodium solution and subretinal injection to the formed in macule space 0.1-0.2 ml of platelet-rich autolplasma. Results. As a result of the treatment according to this technique during the long-term period after the surgery (1 to 9 months) thickness of fovea reduced to 85-150 µm in average staying stable during the whole observation period. In 9 patients pigment epithelium thickened from 24 to 38 µm in parafoveolar area and fovea area. Corrected vision in 3 patients reached 0.1, and in the rest it did not exceed 0.06, herewith, all patients noted consistently improved vision. All patients had favorable evolution of photosensitivity according to microperimetry in average from 0.1-0.5 to 8.5-11 dB with a tendency of fixation point movement from periphery to the center. Conclusion. Vitreoretinal surgery 25+, 27 Ga for nonexudative forms of central chorioretinal dystrophy with the use of subretinal injection of platelet-rich autoplasma is a microinvasive, safe, effective method of the treatment of such pathology improving vision characteristics and anatomical and physiological characteristics of the eye involved.

Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis

2019 ◽  
Vol 50 (10) ◽  
pp. 661-663 ◽  
Author(s):  
Rehan M. Hussain ◽  
Kimberly D. Tran ◽  
Albert M. Maguire ◽  
Audina M. Berrocal
Keyword(s):  
Leber’S Congenital Amaurosis ◽  
Subretinal Injection

scholarly journals Autosomal Dominant Retinitis Pigmentosa Due to Class B Rhodopsin Mutations: An Objective Outcome for Future Treatment Trials

2019 ◽  
Vol 20 (21) ◽  
pp. 5344 ◽  
Author(s):  
Alexander Sumaroka ◽  
Artur V. Cideciyan ◽  
Jason Charng ◽  
Vivian Wu ◽  
Christian A. Powers ◽  
...  
Keyword(s):  
Canine Model ◽  
Response To Therapy ◽  
Therapeutic Effects ◽  
Cross Sectional ◽  
Early Phase Trials ◽  
Slow Progression ◽  
Class B ◽  
Objective Outcome ◽  
Photoreceptor Death ◽  
Subretinal Injection

Gene therapy for adRP due to RHO mutations was recently shown to prevent photoreceptor death in a canine model of Class B disease. Among translational steps to be taken, one is to determine a method to detect efficacy in a human clinical trial. The relatively slow progression of adRP becomes a difficulty for clinical trials requiring an answer to whether there is slowed progression of degeneration in response to therapy. We performed a single-center, retrospective observational study of cross-sectional and longitudinal data. The study was prompted by our identification of a pericentral disease distribution in Class B RHO-adRP. Ultrawide optical coherence tomography (OCT) scans were used. Inferior retinal pericentral defects was an early disease feature. Degeneration further inferior in the retina merged with the pericentral defect, which extended into superior retina. In about 70% of patients, there was an asymmetric island of structure with significantly greater superior than inferior ellipsoid zone (EZ) extent. Serial measures of photoreceptor structure by OCT indicated constriction in superior retinal extent within a two-year interval. We conclude that these results should allow early-phase trials of therapy in RHO-adRP to move forward by inclusion of patients with an asymmetric extent of photoreceptor structure and by monitoring therapeutic effects over two years in the superior retina, a reasonable target for subretinal injection.

Sign in / Sign up

Export Citation Format

Share Document